EHT/AGN 0001 is a Phase II-ready, bio-available small molecule in orally clinical development for neuropathic discomfort read all . This agreement between Allergan and Bristol-Myers Squibb also encompasses EHT/AGN 0002 and associated back-up compounds.D., President of ExonHit Therapeutics’ Management Board. Whitcup, M.D., Executive Vice President, Research & Chief and Advancement Scientific Officer at Allergan. ExonHit might also receive potential EHT/AGN 0001 related advancement – and regulatory-based milestone payments exceeding USD $32 million and royalties on future worldwide sales. The effectiveness of the license contract between Bristol-Myers Squibb and Allergan is subject to antitrust clearance by the U.S.
The versatility of our Targeted Secretion Inhibitors platform has enabled Syntaxin to develop exciting proprietary pre-clinical candidates outside pain, in areas such as for example endocrinology and oncology. This provides Syntaxin with a strong foundation to develop extra value from upcoming partnerships with other pharmaceutical and biotechnology businesses.’.. Allergan initiates AGN-214868 Phase II trials in post herpetic neuralgia and overactive bladder Syntaxin, a biotechnology firm developing novel biopharmaceuticals to control cell secretion, announces its partner Allergan today, Inc offers initiated two Stage II trials to judge the basic safety and efficacy of its re-targeted endopeptidase drug candidate AGN-214868.